Nipah Virus C and W Proteins Contribute to Respiratory Disease in Ferrets

Journal of Virology

Volumn 90, Issue 14, 2016, Pages 6326-6343

  Satterfield, Benjamin A ^a,b   Cross, Robert W ^a,b   Fenton, Karla A ^a,b   Borisevich, Viktoriya ^a,b   Agans, Krystle N ^a,b   Deer, Daniel J ^a,b   Graber, Jessica ^a   Basler, Christopher F ^c   Geisbert, Thomas W ^a,b   Mirea, Chad E ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; MACROPHAGE DERIVED CHEMOKINE; MIGRATION INHIBITION FACTOR; MYELOID PROGENITOR INHIBITORY FACTOR 1; NEUTRALIZING ANTIBODY; NIPAH VIRUS C PROTEIN; NIPAH VIRUS W PROTEIN; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; VIRUS PROTEIN; C PROTEIN, NIPAH VIRUS; PHOSPHOPROTEIN; VIRAL PROTEIN; VIRUS ANTIBODY; W PROTEIN, NIPAH VIRUS;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CARBOXY TERMINAL SEQUENCE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FERRET; HEK293 CELL LINE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; HYPOALBUMINEMIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INNATE IMMUNITY; LYMPHOCYTOPENIA; MOLECULAR DYNAMICS; MORTALITY; NIPAH VIRUS; NIPAH VIRUS INFECTION; NONHUMAN; OPEN READING FRAME; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY MICROVASCULAR ENDOTHELIAL CELL; RESPIRATORY TRACT INFECTION; REVERSE GENETICS; SURVIVAL RATE; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL; VERO CELL LINE; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS TITRATION; ANIMAL; CELL CULTURE; CHLOROCEBUS AETHIOPS; COMPLICATION; HAMSTER; HENIPAVIRUS INFECTION; IMMUNOLOGY; METABOLISM; MUSTELA PUTORIUS FURO; PATHOGENICITY; PATHOLOGY; RESPIRATORY TRACT DISEASES; VASCULAR ENDOTHELIUM; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CRICETINAE; ENDOTHELIUM, VASCULAR; FEMALE; FERRETS; HENIPAVIRUS INFECTIONS; HUMANS; NIPAH VIRUS; PHOSPHOPROTEINS; RESPIRATORY TRACT DISEASES; VERO CELLS; VIRAL LOAD; VIRAL PROTEINS;

EID: 84966703801     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00215-16     Document Type: Article

References (62)

1. Goh KJ, Tan CT, Chew NK, Tan PS, Kamarulzaman A, Sarji SA, Wong KT, Abdullah BJ, Chua KB, Lam SK. 2000. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia.NEngl JMed 342:1229-1235. http://dx.doi.org/10.1056/NEJM200004273421701.
2. Wong KT, Shieh WJ, Kumar S, Norain K, Abdullah W, Guarner J, Goldsmith CS, Chua KB, Lam SK, Tan CT, Goh KJ, Chong HT, Jusoh R, Rollin PE, Ksiazek TG, Zaki SR. 2002. Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis. Am J Pathol 161:2153-2167. http://dx.doi.org/10.1016/S0002-9440(10)64493-8.
3. Eaton BT, Broder CC, Middleton D, Wang LF. 2006. Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol 4:23-35. http://dx.doi.org/10.1038/nrmicro1323.
4. Rockx B, Winegar R, Freiberg AN. 2012. Recent progress in henipavirus research: molecular biology, genetic diversity, animal models. Antiviral Res 95:135-149. http://dx.doi.org/10.1016/j.antiviral.2012.05.008.
5. Sejvar JJ, Hossain J, Saha SK, Gurley ES, Banu S, Hamadani JD, Faiz MA, Siddiqui FM, Mohammad QD, Mollah AH, Uddin R, Alam R, Rahman R, Tan CT, Bellini W, Rota P, Breiman RF, Luby SP. 2007. Long-term neurological and functional outcome in Nipah virus infection. Ann Neurol 62:235-242. http://dx.doi.org/10.1002/ana.21178.
6. Chua KB, Goh KJ, Wong KT, Kamarulzaman A, Tan PS, Ksiazek TG, Zaki SR, Paul G, Lam SK, Tan CT. 1999. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 354:1257-1259. http://dx.doi.org/10.1016/S0140-6736(99)04299-3.
7. Arankalle VA, Bandyopadhyay BT, Ramdasi AY, Jadi R, Patil DR, Rahman M, Majumdar M, Banerjee PS, Hati AK, Goswami RP, Neogi DK, Mishra AC. 2011. Genomic characterization of Nipah virus, West Bengal, India. Emerg Infect Dis 17:907-909. http://dx.doi.org/10.3201/eid1705.100968.
8. Hsu VP, Hossain MJ, Parashar UD, Ali MM, Ksiazek TG, Kuzmin I, Niezgoda M, Rupprecht C, Bresee J, Breiman RF. 2004. Nipah virus encephalitis reemergence, Bangladesh. Emerg Infect Dis 10:2082-2087. http://dx.doi.org/10.3201/eid1012.040701.
9. Chadha MS, Comer JA, Lowe L, Rota PA, Rollin PE, Bellini WJ, Ksiazek TG, Mishra A. 2006. Nipah virus-associated encephalitis outbreak, Siliguri, India. Emerg Infect Dis 12:235-240. http://dx.doi.org/10.3201/eid1202.051247.
10. Harcourt BH, Lowe L, Tamin A, Liu X, Bankamp B, Bowden N, Rollin PE, Comer JA, Ksiazek TG, Hossain MJ, Gurley ES, Breiman RF, Bellini WJ, Rota PA. 2005. Genetic characterization of Nipah virus, Bangladesh, 2004. Emerg Infect Dis 11:1594-1597. http://dx.doi.org/10.3201/eid1110.050513.
11. Hossain MJ, Gurley ES, Montgomery JM, Bell M, Carroll DS, Hsu VP, Formenty P, Croisier A, Bertherat E, Faiz MA, Azad AK, Islam R, Molla MA, Ksiazek TG, Rota PA, Comer JA, Rollin PE, Luby SP, Breiman RF. 2008. Clinical presentation of Nipah virus infection in Bangladesh. Clin Infect Dis 46:977-984. http://dx.doi.org/10.1086/529147.
12. Luby SP, Hossain MJ, Gurley ES, Ahmed BN, Banu S, Khan SU, Homaira N, Rota PA, Rollin PE, Comer JA, Kenah E, Ksiazek TG, Rahman M. 2009. Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001-2007. Emerg Infect Dis 15:1229-1235. http://dx.doi.org/10.3201/eid1508.081237.
13. Ching PKG, de los Reyes VC, Sucaldito MN, Tayag E, Columna-Vingno AB, Malbas FF, Jr, Bolo GC, Jr, Sejvar JJ, Eagles D, Playford G, Dueger E, Kaku Y, Morikawa S, Kuroda M, Marsh GA, McCullough S, Foxwell AR. 2015. Outbreak of henipavirus infection, Philippines, 2014. Emerg Infect Dis http://dx.doi.org/10.3201/eid2102.141433.
14. Georges-Courbot MC, Contamin H, Faure C, Loth P, Baize S, Leyssen P, Neyts J, Deubel V. 2006. Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection. Antimicrob Agents Chemother 50:1768-1772. http://dx.doi.org/10.1128/AAC.50.5.1768-1772.2006.
15. Halpin K, Mungall BA. 2007. Recent progress in henipavirus research. Comp Immunol Microbiol Infect Dis 30:287-307. http://dx.doi.org/10.1016/j.cimid.2007.05.008.
16. Satterfield BA, Cross RW, Fenton KA, Agans KN, Basler CF, Geisbert TW, Mire CE. 2015. The immunomodulating V andWproteins of Nipah virus determine disease course. NatCommun6:7483. http://dx.doi.org/10.1038/ncomms8483.
17. Field H, Young P, Yob JM, Mills J, Hall L, Mackenzie J. 2001. The natural history of Hendra and Nipah viruses. Microbes Infect 3:307-314. http://dx.doi.org/10.1016/S1286-4579(01)01384-3.
18. Ksiazek TG, Rota PA, Rollin PE. 2011. A review of Nipah and Hendra viruses with an historical aside. Virus Res 162:173-183. http://dx.doi.org/10.1016/j.virusres.2011.09.026.
19. Weingartl HM, Berhane Y, Czub M. 2009. Animal models of henipavirus infection: a review. Vet J 181:211-220. http://dx.doi.org/10.1016/j.tvjl.2008.10.016.
20. Lo MK, Rota PA. 2008. The emergence of Nipah virus, a highly pathogenic paramyxovirus. J Clin Virol 43:396-400. http://dx.doi.org/10.1016/j.jcv.2008.08.007.
21. Wong KT, Grosjean I, Brisson C, Blanquier B, Fevre-Montange M, Bernard A, Loth P, Georges-Courbot MC, Chevallier M, Akaoka H, Marianneau P, Lam SK, Wild TF, Deubel V. 2003. A golden hamster model for human acute Nipah virus infection. Am J Pathol 163:2127-2137. http://dx.doi.org/10.1016/S0002-9440(10)63569-9.
22. Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, McEachern JA, Green D, Hancock TJ, Chan YP, Hickey AC, Dimitrov DS, Wang LF, Broder CC. 2009. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus infection. PLoS Pathog 5:e1000642. http://dx.doi.org/10.1371/journal.ppat.1000642.
23. Geisbert TW, Daddario-DiCaprio KM, Hickey AC, Smith MA, Chan YP, Wang LF, Mattapallil JJ, Geisbert JB, Bossart KN, Broder CC. 2010. Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PLoS One 5:e10690. http://dx.doi.org/10.1371/journal.pone.0010690.
24. Rockx B, Brining D, Kramer J, Callison J, Ebihara H, Mansfield K, Feldmann H. 2011. Clinical outcome of henipavirus infection in hamsters is determined by the route and dose of infection. J Virol 85:7658-7671. http://dx.doi.org/10.1128/JVI.00473-11.
25. Mire CE, Versteeg KM, Cross RW, Agans KN, Fenton KA, Whitt MA, Geisbert TW. 2013. Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease. Virol J 10: 353. http://dx.doi.org/10.1186/1743-422X-10-353.
26. Park MS, Shaw ML, Munoz-Jordan J, Cros JF, Nakaya T, Bouvier N, Palese P, Garcia-Sastre A, Basler CF. 2003. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDVVprotein and the Nipah virus V, W, andCproteins. J Virol 77:1501-1511. http://dx.doi.org/10.1128/JVI.77.2.1501-1511.2003.
27. Kulkarni S, Volchkova V, Basler CF, Palese P, Volchkov VE, Shaw ML. 2009. Nipah virus edits its P gene at high frequency to express the V andW proteins. J Virol 83:3982-3987. http://dx.doi.org/10.1128/JVI.02599-08.
28. Lo MK, Harcourt BH, Mungall BA, Tamin A, Peeples ME, Bellini WJ, Rota PA. 2009. Determination of the henipavirus phosphoprotein gene mRNA editing frequencies and detection of the C, V and W proteins of Nipah virus in virus-infected cells. J Gen Virol 90:398-404. http://dx.doi.org/10.1099/vir.0.007294-0.
29. Yoneda M, Guillaume V, Sato H, Fujita K, Georges-Courbot MC, Ikeda F, Omi M, Muto-Terao Y, Wild TF, Kai C. 2010. The nonstructural proteins of Nipah virus play a key role in pathogenicity in experimentally infected animals. PLoS One 5:e12709. http://dx.doi.org/10.1371/journal.pone.0012709.
30. Shaw ML, Garcia-Sastre A, Palese P, Basler CF. 2004. Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J Virol 78:5633-5641. http://dx.doi.org/10.1128/JVI.78.11.5633-5641.2004.
31. Lo MK, Miller D, Aljofan M, Mungall BA, Rollin PE, Bellini WJ, Rota PA. 2010. Characterization of the antiviral and inflammatory responses against Nipah virus in endothelial cells and neurons. Virology 404:78-88. http://dx.doi.org/10.1016/j.virol.2010.05.005.
32. Childs K, Stock N, Ross C, Andrejeva J, Hilton L, Skinner M, Randall R, Goodbourn S. 2007. mda-5, but not RIG-I, is a common target for paramyxovirus V proteins. Virology 359:190-200. http://dx.doi.org/10.1016/j.virol.2006.09.023.
33. Childs K, Randall R, Goodbourn S. 2012. Paramyxovirus V proteins interact with the RNA helicase LGP2 to inhibit RIG-I-dependent interferon induction. J Virol 86:3411-3421. http://dx.doi.org/10.1128/JVI.06405-11.
34. Davis ME, Wang MK, Rennick LJ, Full F, Gableske S, Mesman AW, Gringhuis SI, Geijtenbeek TBH, Duprex WP, Gack MU. 2014. Antagonism of the phosphatase PP1 by the measles virus V protein is required for innate immune escape of MDA5. Cell Host Microbe 16:19-30. http://dx.doi.org/10.1016/j.chom.2014.06.007.
35. Rodriguez JJ, Parisien JP, Horvath CM. 2002. Nipah virus V protein evades alpha and gamma interferons by preventing STAT1 and STAT2 activation and nuclear accumulation. J Virol 76:11476-11483. http://dx.doi.org/10.1128/JVI.76.22.11476-11483.2002.
36. Shaw ML, Cardenas WB, Zamarin D, Palese P, Basler CF. 2005. Nuclear localization of the Nipah virus W protein allows for inhibition of both virus-and Toll-like receptor 3-triggered signaling pathways. J Virol 79: 6078-6088. http://dx.doi.org/10.1128/JVI.79.10.6078-6088.2005.
37. Basler CF. 2012. Nipah and Hendra virus interactions with the innate immune system. Curr Top Microbiol Immunol 359:123-152. http://dx.doi.org/10.1007/82_2012_209.
38. Lo MK, Søgaard TM, Karlin DG. 2014. Evolution and structural organization of the C proteins of Paramyxovirinae. PLoS One 9:e90003. http://dx.doi.org/10.1371/journal.pone.0090003.
39. Lo MK, Peeples ME, Bellini WJ, Nichol ST, Rota PA, Spiropoulou CF. 2012. Distinct and overlapping roles of Nipah virus P gene products in modulating the human endothelial cell antiviral response. PLoS One 7:e47790. http://dx.doi.org/10.1371/journal.pone.0047790.
40. Yamaguchi M, Kitagawa Y, Zhou M, Itoh M, Gotoh B. 2014. An anti-interferon activity shared by paramyxovirus C proteins: inhibition of Toll-like receptor 7/9-dependent alpha interferon induction. FEBS Lett 588:28-34. http://dx.doi.org/10.1016/j.febslet.2013.11.015.
41. Mathieu C, Guillaume V, Volchkova VA, Pohl C, Jacquot F, Looi RY, Wong KT, Legras-Lachuer C, Volchkov VE, Lachuer J, Horvat B. 2012. Nonstructural Nipah virus C protein regulates both the early host proinflammatory response and viral virulence. J Virol 86:10766-10775. http://dx.doi.org/10.1128/JVI.01203-12.
42. Ciancanelli MJ, Volchkova VA, Shaw ML, Volchkov VE, Basler CF. 2009. Nipah virus sequesters inactive STAT1 in the nucleus via a P geneencoded mechanism. J Virol 83:7828-7841. http://dx.doi.org/10.1128/JVI.02610-08.
43. Buchholz UJ, Finke S, Conzelmann KK. 1999. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 73:251-259.
44. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
45. Takeshita Y, Ransohoff RM. 2012. Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev 248:228-239. http://dx.doi.org/10.1111/j.1600-065X.2012.01127.x.
46. Devaux P, Hodge G, McChesney MB, Cattaneo R. 2008. Attenuation of V-or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys. J Virol 82:5359-5367. http://dx.doi.org/10.1128/JVI.00169-08.
47. von Messling V, Svitek N, Cattaneo R. 2006. Receptor (SLAM [CD150]) recognition and the V protein sustain swift lymphocyte-based invasion of mucosal tissue and lymphatic organs by a morbillivirus. J Virol 80:6084-6092. http://dx.doi.org/10.1128/JVI.00357-06.
48. Pfaller CK, Mastorakos GM, Matchett WE, Ma X, Samuel CE, Cattaneo R. 2015. Measles virus defective interfering RNAs are generated frequently and early in the absence of C protein and can be destabilized by adenosine deaminase acting on RNA-1-like hypermutations. J Virol 89:7735-7747. http://dx.doi.org/10.1128/JVI.01017-15.
49. Devaux P, Cattaneo R. 2004. Measles virus phosphoprotein gene products: conformational flexibility of the P/V protein amino-terminal domain and C protein infectivity factor function. J Virol 78:11632-11640. http://dx.doi.org/10.1128/JVI.78.21.11632-11640.2004.
50. Ng BY, Lim CC, Yeoh A, Lee WL. 2004. Neuropsychiatric sequelae of Nipah virus encephalitis. J Neuropsychiatry Clin Neurosci 16:500-504. http://dx.doi.org/10.1176/jnp.16.4.500.
51. Geisbert TW, Mire CE, Geisbert JB, Chan YP, Agans KN, Feldmann F, Fenton KA, Zhu Z, Dimitrov DS, Scott DP, Bossart KN, Feldmann H, Broder CC. 2014. Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. Sci Transl Med 6:242ra82. http://dx.doi.org/10.1126/scitranslmed.3008929.
52. Hooper DC, Phares TW, Fabis MJ, Roy A. 2009. The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system. PLoS Negl Trop Dis 3:e535. http://dx.doi.org/10.1371/journal.pntd.0000535.
53. Murphy FA. 1977. Rabies pathogenesis. Arch Virol 54:279-297. http://dx.doi.org/10.1007/BF01314774.
54. Mathieu C, Pohl C, Szecsi J, Trajkovic-Bodennec S, Devergnas S, Raoul H, Cosset FL, Gerlier D, Wild TF, Horvat B. 2011. Nipah virus uses leukocytes for efficient dissemination within a host. J Virol 85:7863-7871. http://dx.doi.org/10.1128/JVI.00549-11.
55. Ivey NS, MacLean AG, Lackner AA. 2009. Acquired immunodeficiency syndrome and the blood-brain barrier. J Neurovirol 15:111-122. http://dx.doi.org/10.1080/13550280902769764.
56. Tunkel AR, Rosser SW, Hansen EJ, Scheld WM. 1991. Blood-brain barrier alterations in bacterial meningitis: development of an in vitro model and observations on the effects of lipopolysaccharide. In Vitro Cell Dev Biol 27A:113-120.
57. Bermpohl D, Halle A, Freyer D, Dagand E, Braun JS, Bechmann I, Schroder NW, Weber JR. 2005. Bacterial programmed cell death of cerebral endothelial cells involves dual death pathways. J Clin Invest 115: 1607-1615. http://dx.doi.org/10.1172/JCI23223.
58. Barkhordarian A, Thames AD, Du AM, Jan AL, Nahcivan M, Nguyen MT, Sama N, Chiappelli F. 2015. Viral immune surveillance: toward a TH17/TH9 gate to the central nervous system. Bioinformation 11:47-54. http://dx.doi.org/10.6026/97320630011047.
59. Kamimura D, Yamada M, Harada M, Sabharwal L, Meng J, Bando H, Ogura H, Atsumi T, Arima Y, Murakami M. 2013. The gateway theory: bridging neural and immune interactions in the CNS. Front Neurosci 7:204. http://dx.doi.org/10.3389/fnins.2013.00204.
60. Lamp B, Dietzel E, Kolesnikova L, Sauerhering L, Erbar S, Weingartl H, Maisner A. 2013. Nipah virus entry and egress from polarized epithelial cells. J Virol 87:3143-3154. http://dx.doi.org/10.1128/JVI.02696-12.
61. Devaux P, Hudacek AW, Hodge G, Reyes-Del Valle J, McChesney MB, Cattaneo R. 2011. A recombinant measles virus unable to antagonize STAT1 function cannot control inflammation and is attenuated in rhesus monkeys. J Virol 85:348-356. http://dx.doi.org/10.1128/JVI.00802-10.
62. Svitek N, Gerhauser I, Goncalves C, Grabski E, Doring M, Kalinke U, Anderson DE, Cattaneo R, von Messling V. 2014. Morbillivirus control of the interferon response: relevance of STAT2 and mda5 but not STAT1 for canine distemper virus virulence in ferrets. J Virol 88:2941-2950. http://dx.doi.org/10.1128/JVI.03076-13.